Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions
Journal of Anesthesia and Translational Medicine,
Год журнала:
2024,
Номер
3(3), С. 65 - 75
Опубликована: Июль 11, 2024
Ketamine,
a
dissociative
anesthetic,
is
widely
utilized
in
both
human
and
veterinary
anesthesia.
Its
(S)-enantiomer,
esketamine,
similarly
employed
for
anesthesia
analgesia.
The
anesthetic
effects
of
ketamine
esketamine
arise
from
their
antagonism
the
N-methyl-D-aspartate
receptor
(NMDAR).
In
field
psychiatry,
rapid-acting
antidepressant
properties
severe
depression
have
generated
significant
interest,
resulting
its
increased
off-label
usage
United
States
(U.S.).
2019,
nasal
spray
received
approval
use
U.S.
Europe.
However,
concerns
emerged
regarding
potential
adverse
effects,
including
long-term
efficacy,
addiction
risks,
suicide
risk
clinical
settings.
contrast,
arketamine,
(R)-enantiomer
ketamine,
exhibits
superior
longer-lasting
rodent
models
depression,
with
fewer
side
compared
to
esketamine.
Nevertheless,
research
on
efficacy
safety
arketamine
patients
remains
limited.
This
article
provides
concise
exploration
historical
two
enantiomers
while
also
delving
into
future
directions
application
these
fields.
Язык: Английский
Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials
Clinical & Translational Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 5, 2025
Язык: Английский
The effect of esketamine combined with sufentanil based patient-controlled intravenous analgesia for postoperative pain in patients undergoing third molar surgery and maxillofacial trauma: a randomized clinical trial
BMC Oral Health,
Год журнала:
2024,
Номер
24(1)
Опубликована: Дек. 2, 2024
This
study
aims
to
investigate
the
effects
of
combining
esketamine
with
sufentanil
for
postoperative
patient-controlled
intravenous
analgesia
(PCIA)
in
patients
undergoing
elective
impacted
tooth
surgery
or
open
reduction
and
internal
fixation.
In
this
single-center,
prospective,
double-blinded,
randomized,
parallel-controlled
trial,
91
were
randomly
divided
into
two
groups.
The
experimental
group
(group
ES,
n
=
46)
received
a
combination
1.5
µg/kg
1.0
mg/kg,
while
control
S,
45)
2
alone
PCIA
after
surgery.
Primary
outcome
was
assessed
using
Visual
Analogue
Scale
(VAS)
at
rest
during
mouth
opening
6
h,
12
24
48
h
post-surgery.
Secondary
outcomes
included
Ramsay
Sedation
(RSS)
scores,
Quality
Recovery-15
(QoR-15)
patient
satisfaction
analgesia,
occurrence
adverse
events
within
frequency
button
presses
number
requiring
rescue
also
recorded.
resting
VAS
scores
mouth-opening
post-surgery
significantly
lower
Group
ES
than
S
(P
<
0.05).
Additionally,
RSS
higher
0.032)
0.021)
ES.
use
decreased
QoR-15
increased
0.001
P
0.001,
respectively).
incidences
dizziness
nausea/vomiting
reduced
0.045
0.036,
respectively)
but
one
event
nightmare
observed.
There
no
significant
difference
between
combined
third
molar
maxillofacial
trauma
can
alleviate
short-term
pain,
improve
quality
recovery.
Esketamine
is
worth
promoting
clinical
application
oral
retrospectively
registered
chictr.org.cn
identifier:
ChiCTR2400086662
on
08/07/2024.
Язык: Английский